AARD Stock Forecast: Aardvark Therapeutics, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Aardvark Therapeutics, Inc. hold a median 12-month price target of $2.5 — +168.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Aardvark Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (55): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (6): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AARD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AARD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +168.3% from it.
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Jones Trading | Maintains | Buy | $19 → $10 |
| 26 Oct 2026 | HC Wainwright & Co. | Maintains | Neutral | $4.00 → $2.00 |
| 19 Oct 2026 | HC Wainwright & Co. | Maintains | Neutral | $6.00 → $4.00 |
| 24 Sept 2026 | RBC Capital | Reiterates | Sector Perform | $6.00 |
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | $6.00 |
| 15 May 2026 | B. Riley Securities | Maintains | Buy | $8.00 → $7.00 |
| 15 May 2026 | BTIG | Downgrade | Neutral | — |
| 15 May 2026 | Morgan Stanley | Downgrade | Underweight | $7.00 → $3.00 |
| 24 Mar 2026 | BTIG | Reiterates | Buy | — |
| 2 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 2 Mar 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 2 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 2 Mar 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 2 Mar 2026 | Stifel | Downgrade | Hold | — |
| 10 Feb 2026 | BTIG | Reiterates | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Dec 2025 | Oppenheimer | Initiates | Outperform | — |
| 12 Dec 2025 | William Blair | Initiates | Outperform | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AARD.
This page is one stock. Monday covers all of them.
AARD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AARD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Aardvark Therapeutics, Inc. returned −90.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AARD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −66.0%
- Return on assets
- −40.4%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aardvark Therapeutics, Inc. has a market value of $21.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$69.9M.
Diluted earnings per share, trailing twelve months: −$3.21.
Free cash flow in the twelve months to 30 June 2026: −$69.4M.
Aardvark Therapeutics, Inc. employs 28 people.
Data provided by Twelve Data
AARD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AARD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Aardvark Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AARD
What is the AARD stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Aardvark Therapeutics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $1.5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AARD stock a buy right now?
Of the 11 analysts covering Aardvark Therapeutics, Inc., 4 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Aardvark Therapeutics, Inc. 15 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AARD?
As at 21 Nov 2026, Aardvark Therapeutics, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (55 of 100).
Will AARD stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +168.3% from the last close, and Ticker Nerd's factor model ranks Aardvark Therapeutics, Inc. 15 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AARD stock forecast for 2030?
No analyst covering Aardvark Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $10 over the next 12 months.
How has AARD stock performed over the past year?
Aardvark Therapeutics, Inc. returned -90.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aardvark Therapeutics, Inc. do?
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions. The company’s current work centers on oral, gut-restricted drug candidates designed to activate bitter taste receptors in the digestive tract and influence satiety signaling through the gut-brain axis.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions. The company’s current work centers on oral, gut-restricted drug candidates designed to activate bitter taste receptors in the digestive tract and influence satiety signaling through the gut-brain axis. Its lead program, ARD-101, is being developed for hyperphagia associated with Prader-Willi syndrome and other hunger-associated rare diseases, while additional programs explore applications in obesity and related metabolic disorders. Aardvark Therapeutics operates in the biopharmaceutical and health technology sectors, with a research-driven model built around advancing investigational therapies through clinical development for conditions with limited treatment options. Founded in 2017 and headquartered in San Diego, California, the company focuses on translating its proprietary science into targeted treatments for patients affected by metabolic and inflammatory disease pathways.
CEO Dr. Tien-Li Lee M.D. · 28 employees · United States · https://aardvarktherapeutics.com